Design, synthesis and biological evaluation of l-dopa amide derivatives as potential prodrugs for the treatment of Parkinson’s disease

Design, synthesis and biological evaluation of l-dopa amide derivatives as potential prodrugs for the treatment of Parkinson’s disease Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as l-DOPA prodrugs A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl]propane-1,2,3-triol Synthesis and pharmacological activities of a novel tripeptide mimetic dopamine prodrug Synthesis and Study of<scp>l</scp>-Dopa−Glutathione Codrugs as New Anti-Parkinson Agents with Free Radical Scavenging Properties Codrugs Linking <scp>l</scp>-Dopa and Sulfur-Containing Antioxidants: New Pharmacological Tools against Parkinson’s Disease The formation of 3-hydroxy-4-methoxyphenylalanine and 3-hydroxy-4-methoxyphenethylamine in plasma during L-DOPA therapy in patients with parkinson's disease. Adamantane and protoadamantanealkanamines as potential anti-Parkinson agents. 10 Troponoids. 6. Troponylpiperazines: a new class of dopamine agonists Synthesis of 3-(5-bromo-2,3-dimethoxy-phenyl)-[1, 2, 4] oxadiazole analogues and their evaluation as anti-Parkinson′s agents